作者:Tina S. Rasmussen、Heidi Koldsø、Shinpei Nakagawa、Atsushi Kato、Birgit Schiøtt、Henrik H. Jensen
DOI:10.1039/c1ob06038d
日期:——
CPT-11 (also called Irinotecan). We have prepared a new compound of the nortropane-type, uronic-Noeurostegine, and demonstrated that this is a competitive and potent E. coliβ-glucuronidase inhibitor, while inhibition of the mammalian β-glucuronidase from bovine liver was found to be less significant. Although not intended, two other compounds having N-ethyl and N-(4-hydroxybutyl) substituents were also
最近显示,抑制β-葡萄糖醛酸苷酶可用于减轻常见结肠癌化学疗法CPT-11(也称为CPT-11)的药物毒性 伊立替康)。我们已经制备的去甲莨菪烷型,的新化合物的糖醛-Noeurostegine,并证明了这是竞争性的和有效的大肠杆菌β葡糖醛酸酶抑制剂,而来自牛肝脏哺乳动物β葡萄糖醛酸酶的抑制被认为是少显著。尽管无意,但由于最后步骤中脱苄基反应缓慢,在本研究中还制备了另外两种具有N-乙基和N-(4-羟基丁基)取代基的化合物。的Ñ -取代基被认为是来自与用于感溶剂反应乙醇和THF。与母体化合物相比,这些化合物还抑制了两种β-葡糖醛酸糖苷酶,尽管程度较小。此外,还评估了Noeurostegine和三种糖醛酸-Noeurostegines作为对多种糖苷酶的抑制剂,前者对大鼠肠道乳糖酶和海藻糖酶表现出有效的抑制作用,而后者则无活性。